4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.
4FRONT-1 trial evaluates 4D-150 against aflibercept in wet AMD, focusing on visual acuity and treatment burden reduction over 52 weeks. 4D-150 offers sustained anti-VEGF delivery via a single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback